Adverse events in all cohorts in Ad5-IL-12 gene therapy trial.
toxicity
ADVERSE EVENTS, ADVERSE EVENT
All the Adverse events (AEs) collected through primary toxicity endpoint (day 30) are collected and are arranged by method of collection. No adverse events measured for Patient #3 due to consent withdrawal.